Shares of Eagle Pharmaceuticals EGRX were flat in pre-market trading after the company reported Q2 results.
Earnings per share decreased 32.14% year over year to $0.57, which beat the estimate of $0.26.
Revenue of $41,938,000 decreased by 26.04% year over year, which missed the estimate of $42,280,000.
Earnings guidance hasn't been issued by the company for now.
Eagle Pharmaceuticals hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 10, 2020
Time: 08:30 AM
ET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestor.eagleus.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2402260&sessionid=1&key=0129C521D736B325C69279B72A2EEA31®Tag=&sourcepage=register
Company's 52-week high was at $64.94
Company's 52-week low was at $33.80
Price action over last quarter: down 13.26%
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.